ResearcherNanchang UniversityActive in the last 2 years

Ji-Long Hu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5080495621. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

High Level of Adropin Promotes the Progression of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2174/0115680096267203231024093601 ↗
Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer. Co-author DOI 10.1155/2021/5589342 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zhinan Zheng · 2 shared papers, 2021–2024 · strength 0.41
- Paper High Level of Adropin Promotes the Progression of Pancreatic Ductal Adenocarcinoma. DOI 10.2174/0115680096267203231024093601 ↗
- Paper Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer. DOI 10.1155/2021/5589342 ↗
Chuanjun Chen · 1 shared paper, 2021 · strength 0.15
- Paper Targeting the EZH2-PPAR Axis Is a Potential Therapeutic Pathway for Pancreatic Cancer. DOI 10.1155/2021/5589342 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.